Focus: Abbott is a diversified healthcare giant with $40.1B in revenue, operating across pharmaceuticals, medical devices, and diagnostics with a strong presence in cardiovascular, immunology, and metabolic disease markets. Publicly traded (ABT) with a market-leading device manufacturing specialty.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
Hot — 3668 jobs added in 30d
Net +1680 (3668 new, 1988 removed). Aggressive expansion phase.
Recent layoff filing — 53 affected
Source: state DOL filings via Big Local News
Abbott is a stable, well-funded big pharma employer with abundant openings, but high revenue concentration and recent restructuring create uncertainty around long-term role security.
Represents 70% of company revenue but approaching loss of exclusivity, creating existential dependency risk.
Help build intelligence for Abbott
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Abbott's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic antihypertensive in post-exclusivity phase with modest Medicare spending.
Generic aminoglycoside antibiotic with minimal market penetration.
Fixed-dose combination product in mature generic market.
Amino acid parenteral nutrition formulation awaiting launch.
Classic antipsychotic in early-stage development or relaunch.
130 discontinued, 0 duplicate formulations not shown
Abbott Laboratories jumps after six straight sessions of losses (ABT:NYSE) - Seeking Alpha
Abbott Laboratories jumps after six straight sessions of losses (ABT:NYSE) Seeking Alpha
Abbott agrees to settlement over closure of largest baby formula plant in U.S. - The Tribune-Democrat
Abbott agrees to settlement over closure of largest baby formula plant in U.S. The Tribune-Democrat
Abbott agrees to settlement over closure of largest baby formula plant in the US - MyNorthwest.com
Abbott agrees to settlement over closure of largest baby formula plant in the US MyNorthwest.com
Abbott Laboratories Share Price - ABT, RNS News, Articles, Quotes, & Charts (NYSE:ABT) - Proactive financial news
Abbott Laboratories Share Price - ABT, RNS News, Articles, Quotes, & Charts (NYSE:ABT) Proactive financial news
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know Yahoo Finance
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript - fortune.com
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript fortune.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent layoffs represent 0.3% of the company but signal targeted facility/product rationalization in manufacturing and distribution; combined with revenue decline and DEPAKOTE cliff, expect 12-24 months of continued headcount volatility.
Recent peer-reviewed publications with author affiliations at this company
Assessment of Biochemical Analytes Stability: The Role of Centrifugation and Storage Conditions in the Preanalytical Phase.
Hidden nutritional inadequacy in U.S. children with obesity: Evidence from National Health and Nutrition Examination Survey 2021-2023.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo